Greenridge Exploration Inc. ("Greenridge" or the "Company")  is pleased to announce the completion of a high-resolution helicopter-borne Mobile MagnetoTellurics System ("MobileMT") survey at the Sabre ...

Alberta College of Aeronautics, based in Canada, has acquired an AL42 simulator which is an exact replica of the Diamond DA42 ...

ALX Nigeria has unveiled Creative Tech Lite, a new initiative designed to equip the continent’s creators with in-demand digital skills. Touted as a game-changer for Africa’s creative economy ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping ...

Lab-grown diamonds (LGDs) are gaining traction as an ethical and sustainable alternative to mined diamonds, dispelling common misconceptions about their quality and environmental impact.

ALX has officially launched its innovative program, Creative Tech Lite, CTL, aimed at empowering Africa’s creative talent with essential tech skills. The launch event, held at ALX Nigeria’s ...

Navigating the diamond world can be simplified by understanding the 4Cs: cut, color, clarity, and carat. Lab-grown diamonds offer a cost-effective and eco-conscious alternative, gaining popularity ...

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker evorpacept, when added to Merck’s (MRK) anti-PD-1 ...

ALX Oncology Holdings Inc., a pharmaceutical company based in South San Francisco, California, has been notified of its non-compliance with a Nasdaq listing requirement. On April 23, 2025, the ...

Alexander’s, Inc. (NYSE: ALX) is a real estate investment trust (“REIT”), incorporated in Delaware, engaged in leasing, managing, developing and redeveloping its properties. All references ...

The actress — and PEOPLE's World's Most Beautiful is being honored as one of 2025's Icons, wearing custom Gap Studio by Zac Posen Catherine Santino is a Style Writer-Reporter at PEOPLE.

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and ...